THE 60-SECOND GUIDE
TRH
Established biology · indication-specific medicine.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Thyrotropin-releasing hormone, or TRH, is a tiny chemical message from the brain that prompts the pituitary to release thyroid-stimulating hormone. It also influences prolactin release. Its importance lies in explaining how the brain directs other hormone-producing organs. [1]
Potential benefits
Stimulates pituitary release of thyroid-stimulating hormone. Also stimulates prolactin release. Its discovery demonstrated that the brain controls pituitary hormones through chemical messengers. [1]
Evidence & its limits
A foundational hormone discovery does not establish broad neurological treatment claims. For example, the FDA record for protirelin in amyotrophic lateral sclerosis lists an orphan designation that was withdrawn or revoked and states that the orphan indication was not approved. Designation is not evidence of therapeutic success. [1]
Risks & unknowns
TRH is not an approved consumer wellness treatment. Historical diagnostic administration could cause nausea, flushing, urinary urgency, or transient cardiovascular effects. Research compounds may have uncertain identity and safety. [1]
Status & scope
TRH is not an approved consumer wellness treatment. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- FDA: protirelin ALS orphan-designation record
- Salk Institute history
- 1977 Nobel announcement
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.